This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The nation’s publicly traded hospicecompanies are primed for more acquisitions after a 2023 slump, fueled by census and growth. Transaction volume declined in the hospice and home-based care space in 2023, following the two record-breaking prior years. raise compared to Q1 in 2023. million and $54.6
Hospices are blazing trails toward growth, each provider with its own range of strategies. In 2023, the focus for many is to not only expand their core business but to spread further into the care continuum. In this story, Hospice News highlights the growth strategies of several providers.
Addus expects the transaction to further its goal of co-locating its clinical services in markets where it already has a personalcare footprint. We are pleased to expand our market presence in Tennessee with the addition of the Tennessee Quality Care operations. The company’s net service revenue reached $251.6
Though hospice deal volume dipped in 2022 compared to previous years, five particular transactions could paint a larger picture of where investors see value in the space. These interesting, unusual or groundbreaking deals could signal what’s to come in 2023 and help shape the hospice market’s long-term future. s (NYSE: HUM) $2.8
“The decline certainly is not due to buyer interest, which remains incredibly strong, but rather a limited number of actionable targets of scale,” Palamara told Hospice News. Transaction activity is slightly behind where we thought it would be for 2023, particularly the pace of lower middle market add-on activity.”
In 2022, the hospice community laid the groundwork for a transformational 2023. Centers for Medicare & Medicaid Services (CMS) developed new approaches for enforcing hospice regulations that will become effective on Jan. The insurance company will integrate LHC Group with its existing home health asset, Optum Health.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content